- Home
- NUV vs ZYME Comparison
NUV vs ZYME Comparison
Compare NUV & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | ZYME |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | NUV | ZYME |
|---|---|---|
| Price | $9.03 | $23.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 403.3K | ★ 649.0K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $162.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $8.38 | $9.03 |
| 52 Week High | $9.26 | $28.49 |
Technical Indicators
Market Signals| Indicator | NUV | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 47.53 |
| Support Level | $9.00 | $22.28 |
| Resistance Level | $9.05 | $23.66 |
| Average True Range (ATR) | 0.06 | 1.36 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 8.93 | 16.70 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.